The U.S. in-vitro diagnostics market was valued at USD 32.94 billion in 2022. It is expected to grow from USD 33.78 billion in 2023 to USD 56.81 billion by 2030, with a compound annual growth rate (CAGR) of 7.7% during the forecast period.
This growth is driven by the strong presence of major industry players, an increasing demand for rapid diagnostic tests and point-of-care devices, the rising prevalence of chronic diseases, and growing awareness about the importance of early disease detection.
Market Trend:
The U.S. In-vitro Diagnostics Market is seeing rapid advancements, especially with the rise in demand for precision medicine and personalized healthcare. Technological innovations, such as point-of-care testing, automation, and artificial intelligence, are transforming how diagnostic tests are being conducted. Additionally, there’s an increasing shift towards non-invasive diagnostic methods, which are driving the development of new and more efficient in-vitro diagnostic tools.
Request a Free Sample PDF:
Market Growth
The U.S. In-vitro Diagnostics Market is projected to grow significantly, fueled by a rising aging population, increasing prevalence of chronic diseases, and greater focus on early disease detection. The growing demand for molecular diagnostics and genetic testing also plays a major role in the expansion of this market. As the healthcare system continues to evolve, there's a shift toward value-based care, further promoting the adoption of in-vitro diagnostic tools to enable faster and more accurate diagnoses.
Market Segmentation:
The U.S. In-vitro Diagnostics Market can be segmented by product type, application, technology, and end-user.
By product type, the market includes reagents, instruments, and software. Reagents dominate the market as they are essential for conducting a variety of diagnostic tests, while instruments such as analyzers and testing devices play a crucial role in executing complex tests. Software solutions, which are used to analyze data, are also becoming increasingly important in improving the accuracy and efficiency of diagnostics in the U.S. In-vitro Diagnostics Market.
When considering application, the U.S. In-vitro Diagnostics Market can be divided into clinical chemistry, hematology, immunodiagnostics, microbiology, and others. Among these, immunodiagnostics is witnessing substantial growth due to its applications in infectious disease testing, cancer diagnostics, and autoimmune disease monitoring. Molecular diagnostics is another rapidly growing segment, driven by its ability to detect diseases at a molecular level with high precision.
In terms of technology, the U.S. In-vitro Diagnostics Market includes traditional diagnostic methods like enzyme-linked immunosorbent assays (ELISA) and newer methods like PCR (polymerase chain reaction) and next-generation sequencing (NGS). PCR-based testing is widely used for genetic testing and detecting infectious diseases, contributing to its strong growth in the market.
The end-user segmentation includes hospitals, diagnostic laboratories, and clinics. Hospitals are the largest segment in the U.S. In-vitro Diagnostics Market, as they require a broad range of diagnostic tests for patient care. Diagnostic laboratories are another major segment, benefiting from the rising demand for outsourced testing services and specialized diagnostic technologies.
Restraining Factors:
While the U.S. In-vitro Diagnostics Market is growing, there are a few challenges. High costs associated with advanced diagnostic tools can limit their accessibility, especially in lower-income regions. Additionally, regulatory hurdles, such as lengthy approval processes for new diagnostic tests, can delay market entry for new technologies. Concerns about data privacy, particularly with genetic testing and digital health tools, are also causing hesitations among consumers and healthcare providers.
Regional Analysis:
The U.S. In-vitro Diagnostics Market is highly concentrated in major healthcare hubs such as California, New York, and Florida, where there is advanced infrastructure and higher healthcare spending. The market is also benefiting from supportive government initiatives and increasing healthcare investments. States with a larger elderly population are seeing the highest growth in demand for diagnostic services. Furthermore, the adoption of digital health tools and telemedicine is expanding the reach of diagnostic services in rural and underserved areas.
Key Industry Developments:
· In February 2023, BD (Becton, Dickinson and Company) received Emergency Use Authorization (EUA) from the USFDA for its molecular diagnostic combination test. This test is designed to detect SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV).
· In October 2022, Thermo Fisher Scientific Inc. announced its agreement to acquire Binding Site Group, a company known for its specialized diagnostic assays and instruments. This acquisition will strengthen Thermo Fisher’s portfolio in the specialty diagnostics sector.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com